Novo Nordisk A/S (NVO) vs Novartis AG (NVS)
Novo Nordisk A/S and Novartis AG are both Drug Manufacturers General companies. Novartis AG is the larger, with a market value of $264.3B against $129.3B — 2.0× the size. Novo Nordisk A/S trades at the lower P/E: 9.5× against 21.8×. Novo Nordisk A/S grew revenue faster over the last twelve months: 13.2% against 2.73%. Novo Nordisk A/S has the higher net margin (35.5% vs 22.5%) and the higher return on invested capital (28.7% vs 13.1%). Both pay a dividend; Novartis AG yields more (3.69% vs 1.36%). Across the 23 metrics below, Novo Nordisk A/S leads on 18 and Novartis AG on 5.
Valuation
Profitability
| Metric | NVO | NVS | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 80.73% | 74.74% | 72.77% |
| Operating margin | 43.36% | 30.17% | 18.90% |
| Net margin | 35.47% | 22.50% | 8.27% |
| Free cash flow margin | 14.79% | 26.77% | 17.25% |
| Return on equity | 60.84% | 30.37% | 6.97% |
| Return on assets | 22.00% | 11.27% | 2.76% |
| Return on invested capital | 28.67% | 13.14% | 6.30% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack